Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Publications

Greer, BE, Koh, W-J, Abu-Rustum, N, Bookman, MA, Bristow, RE, Campos, SM, Cho, KR, Copeland, L, Crispens, MA, Eifel, PJ, Huh, WK, Jaggernauth, W, Kapp, DS, Kavanagh, JJ, III, LJR, Morgan, M, Jr, MRJ, Powell, CB, Remmenga, SW, Reynolds, RK, Secord, AA, Jr, SW, and Teng, N. "Uterine Neoplasms Clinical Practice Guidelines in Oncology." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 7, no. 5 (May 2009): 496-531.

Full Text

Greer, BE, Koh, W-J, Abu-Rustum, N, Bookman, MA, Bristow, RE, Campos, SM, Cho, KR, Copeland, L, Crispens, MA, Eifel, PJ, Huh, WK, Jaggernauth, W, Kapp, DS, Kavanagh, JJ, Lurain, JR, Morgan, M, Morgan, RJ, Powell, CB, Remmenga, SW, Reynolds, RK, Alvarez Secord, A, Small, W, and Teng, N. "Uterine Neoplasms. Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 7, no. 5 (May 2009): 498-531. (Review)

Full Text

Alvarez Secord, A, Bae-Jump, V, Havrilesky, LJ, Calingaert, B, Clarke-Pearson, DL, Soper, JT, and Gehrig, PA. "Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists." Int J Gynecol Cancer 19, no. 3 (April 2009): 447-454.

Full Text

Berchuck, A, Iversen, ES, Luo, J, Clarke, JP, Horne, H, Levine, DA, Boyd, J, Alonso, MA, Secord, AA, Bernardini, MQ, Barnett, JC, Boren, T, Murphy, SK, Dressman, HK, Marks, JR, and Lancaster, JM. "Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 15, no. 7 (April 2009): 2448-2455.

Full Text

Rubatt, JM, Darcy, KM, Hutson, A, Bean, SM, Havrilesky, LJ, Grace, LA, Berchuck, A, and Secord, AA. "Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study." Gynecol Oncol 112, no. 3 (March 2009): 469-474.

Full Text

Fader, AN, Nagel, C, Axtell, AE, Zanotti, KM, Kelley, JL, Moore, KN, Secord, AA, Walsh, CS, Huh, WK, Gehrig, PA, Gibbons, H, Rose, PG, Havrilesky, LJ, Tuller, E, Drake, RD, Bottsford-Miller, J, O'Malley, DM, and UPSC Consortium, . "Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes." Gynecol Oncol 112, no. 3 (March 2009): 558-562.

Full Text

Neubauer, NL, Havrilesky, LJ, Calingaert, B, Bulusu, A, Bernardini, MQ, Fleming, ND, Bland, AE, and Secord, AA. "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma." Gynecol Oncol 112, no. 3 (March 2009): 511-516.

Full Text

Secord, AA, Havrilesky, LJ, O'Malley, DM, Bae-Jump, V, Fleming, ND, Broadwater, G, Cohn, DE, and Gehrig, PA. "A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer." February 2009.

Scholars@Duke

Fader, AN, Starks, D, Rose, PG, Tuller, ER, Gibbons, H, Gehrig, PA, Huh, WK, Havrilesky, LJ, Moore, KN, Axtell, AE, Secord, AA, Kelley, JL, O'Malley, DM, Walsh, C, Drake, RD, Bottsford-Miller, J, and Zanotti, KM. "Early-stage uterine papillary serous carcinoma (UPSC): percentage UPSC, lymphvascular invasion and tumor size are not independent predictors of recurrence." February 2009.

Scholars@Duke

Shafer, A, Ayeni, TA, Deal, AM, Secord, AA, Soper, JT, Havrilesky, LJ, Van Le, L, and Gehrig, PA. "Improved survival with consolidation chemotherapy after adjuvant paclitaxel and carboplatin in advanced epithelial ovarian cancer." February 2009.

Scholars@Duke

Pages